Share Price and Basic Stock Data
Last Updated: November 12, 2025, 5:37 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Cian Healthcare Ltd operates within the pharmaceuticals sector, focusing on delivering healthcare solutions. For the fiscal year ending March 2024, the company reported sales of ₹61.70 Cr, a decline from ₹68.59 Cr in the previous year. This decrease in revenue marks a significant fluctuation, particularly when compared to the peak sales of ₹77.87 Cr recorded in March 2022. The company’s expenses also showed a downward trend, reducing from ₹55.60 Cr in March 2023 to ₹51.30 Cr in the latest fiscal year. This indicates efforts towards cost management amidst fluctuating sales. The overall revenue trajectory suggests volatility, likely influenced by market conditions and competitive pressures. Cian Healthcare’s operating profit for the same period stood at ₹10.40 Cr, down from ₹12.99 Cr, reflecting challenges in maintaining profit margins. The company’s operating profit margin (OPM) was recorded at 16.86%, indicating a slight contraction compared to the previous year’s 18.94%, yet still within a reasonable range for the industry.
Profitability and Efficiency Metrics
Cian Healthcare’s profitability metrics exhibit a mixed performance over the recent years. The net profit for March 2024 was reported at ₹0.25 Cr, a decline from ₹2.03 Cr in the previous fiscal year. This translated into an earnings per share (EPS) of ₹0.10, down from ₹0.81, highlighting the challenges faced by the company in sustaining profitability. The return on equity (ROE) stood at 0.43%, a notable decrease from 3.53% in March 2023, indicating a diminishing return on shareholder investments. Efficiency ratios reflected a cash conversion cycle (CCC) of 235.85 days, which is relatively high, suggesting potential inefficiencies in working capital management. Furthermore, the interest coverage ratio (ICR) was reported at 1.95x, indicating the company is just able to meet its interest obligations, which may raise concerns about financial stability in the face of declining profits.
Balance Sheet Strength and Financial Ratios
The balance sheet of Cian Healthcare reveals a cautious financial position with total borrowings reported at ₹55.69 Cr, down from ₹60.81 Cr in March 2023. This reduction in debt is a positive sign, reflecting a shift towards deleveraging. The company’s reserves stood at ₹32.74 Cr, indicating a modest cushion for future uncertainties. The debt-to-equity ratio was recorded at 0.96x, which is relatively high compared to industry averages, suggesting that the company is still heavily reliant on debt financing. The price-to-book value (P/BV) ratio was reported at 0.89x, indicating that the stock is undervalued relative to its book value. However, the asset turnover ratio of 0.38% indicates that the company may not be utilizing its assets efficiently to generate revenue. Overall, while the company appears to have a stable balance sheet, the high debt levels and low asset efficiency could pose risks to long-term financial health.
Shareholding Pattern and Investor Confidence
Cian Healthcare’s shareholding pattern reflects a significant shift in ownership structure over recent years. As of March 2024, promoters held 27.11% of the company, a drastic decline from 70.89% in September 2021. This reduction in promoter stake may raise concerns among investors regarding management confidence in the company’s future. The public shareholding has increased to 72.89%, indicating a growing interest among retail investors, yet the absence of institutional investors (FIIs and DIIs) could imply a lack of confidence from larger, more risk-averse entities. The total number of shareholders increased to 1,662, suggesting a rising retail investor base. Despite this, the declining promoter share could signal potential risks ahead, as reduced control may lead to challenges in strategic decision-making. Investor sentiment may hinge on the company’s ability to improve its financial performance and restore confidence among its promoters.
Outlook, Risks, and Final Insight
The outlook for Cian Healthcare appears cautiously optimistic, contingent upon its ability to navigate operational challenges and enhance profitability. The company faces risks related to high debt levels, which could impact financial flexibility, especially in volatile market conditions. Moreover, the high cash conversion cycle suggests inefficiencies that may hinder growth. However, the company’s efforts to reduce borrowings and manage expenses may provide a pathway toward improved financial health. Strengths include a strong retail investor base and a focus on cost management, which could enhance operational efficiencies. Moving forward, Cian Healthcare must prioritize improving its operational metrics and restoring profitability to regain investor confidence and stabilize its market position. The company’s ability to effectively manage its debt while optimizing its asset utilization will be critical in shaping its future performance and overall market standing.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Cian Healthcare Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 135 Cr. | 107 | 247/84.3 | 30.7 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.52 Cr. | 1.84 | 4.33/1.82 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,901 Cr. | 450 | 479/192 | 102 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.7 Cr. | 44.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 38.0 Cr. | 26.0 | 29.1/17.0 | 39.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,221.27 Cr | 1,192.93 | 53.76 | 199.56 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric |
|---|
| Sales |
| Expenses |
| Operating Profit |
| OPM % |
| Other Income |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| Net Profit |
| EPS in Rs |
Last Updated: August 19, 2025, 9:10 pm
Below is a detailed analysis of the quarterly data for Cian Healthcare Ltd based on the most recent figures () and their trends compared to the previous period:
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:39 am
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|
| Sales | 57.09 | 73.73 | 77.87 | 68.59 | 61.70 |
| Expenses | 49.74 | 61.74 | 73.52 | 55.60 | 51.30 |
| Operating Profit | 7.35 | 11.99 | 4.35 | 12.99 | 10.40 |
| OPM % | 12.87% | 16.26% | 5.59% | 18.94% | 16.86% |
| Other Income | 0.79 | 0.07 | 0.47 | 0.73 | 1.12 |
| Interest | 7.22 | 7.92 | 6.55 | 6.30 | 6.00 |
| Depreciation | 4.45 | 3.45 | 4.27 | 5.43 | 5.47 |
| Profit before tax | -3.53 | 0.69 | -6.00 | 1.99 | 0.05 |
| Tax % | 7.37% | 91.30% | -7.83% | -2.01% | -400.00% |
| Net Profit | -3.79 | 0.05 | -5.53 | 2.03 | 0.25 |
| EPS in Rs | -1.62 | 0.02 | -2.21 | 0.81 | 0.10 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
|---|---|---|---|---|
| YoY Net Profit Growth (%) | 101.32% | -11160.00% | 136.71% | -87.68% |
| Change in YoY Net Profit Growth (%) | 0.00% | -11261.32% | 11296.71% | -224.39% |
Cian Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 4 years from 2020-2021 to 2023-2024.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -6% |
| TTM: | 27% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 53% |
| TTM: | -8600% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -25% |
| 3 Years: | -43% |
| 1 Year: | -49% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -2% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 2:56 pm
No data available for the Balance Sheet data table.
Cash Flow - No data available for this post.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|
| Debtor Days | 127.80 | 93.56 | 125.24 | 139.58 | 121.15 |
| Inventory Days | 267.18 | 312.78 | 299.94 | 399.93 | 485.99 |
| Days Payable | 220.03 | 209.37 | 270.46 | 295.80 | 371.29 |
| Cash Conversion Cycle | 174.95 | 196.98 | 154.73 | 243.71 | 235.85 |
| Working Capital Days | 14.77 | 16.14 | 38.30 | 40.66 | 26.27 |
| ROCE % | 6.78% | 0.50% | 6.91% | 5.22% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.10 | 0.81 | -2.32 | 0.02 | -1.62 |
| Diluted EPS (Rs.) | 0.10 | 0.81 | -2.32 | 0.02 | -1.62 |
| Cash EPS (Rs.) | 2.29 | 2.98 | -0.50 | 1.50 | 0.28 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 23.10 | 23.00 | 22.19 | 24.92 | 24.90 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 23.10 | 23.00 | 22.19 | 24.93 | 24.91 |
| Revenue From Operations / Share (Rs.) | 24.68 | 27.44 | 31.15 | 31.56 | 24.44 |
| PBDIT / Share (Rs.) | 4.52 | 5.20 | 1.91 | 5.17 | 3.47 |
| PBIT / Share (Rs.) | 2.34 | 3.03 | 0.20 | 3.69 | 1.57 |
| PBT / Share (Rs.) | 0.01 | 0.79 | -2.37 | 0.38 | -1.48 |
| Net Profit / Share (Rs.) | 0.10 | 0.81 | -2.21 | 0.02 | -1.62 |
| NP After MI And SOA / Share (Rs.) | 0.10 | 0.81 | -2.21 | 0.02 | -1.62 |
| PBDIT Margin (%) | 18.32 | 18.94 | 6.14 | 16.37 | 14.20 |
| PBIT Margin (%) | 9.46 | 11.03 | 0.65 | 11.69 | 6.41 |
| PBT Margin (%) | 0.07 | 2.90 | -7.61 | 1.21 | -6.05 |
| Net Profit Margin (%) | 0.41 | 2.95 | -7.10 | 0.07 | -6.63 |
| NP After MI And SOA Margin (%) | 0.41 | 2.95 | -7.10 | 0.07 | -6.63 |
| Return on Networth / Equity (%) | 0.44 | 3.53 | -9.97 | 0.09 | -6.51 |
| Return on Capital Employeed (%) | 6.14 | 7.94 | 0.53 | 8.66 | 3.39 |
| Return On Assets (%) | 0.15 | 1.26 | -3.33 | 0.03 | -2.41 |
| Long Term Debt / Equity (X) | 0.47 | 0.51 | 0.68 | 0.64 | 0.78 |
| Total Debt / Equity (X) | 0.96 | 1.06 | 1.14 | 1.22 | 1.26 |
| Asset Turnover Ratio (%) | 0.38 | 0.44 | 0.43 | 0.49 | 0.00 |
| Current Ratio (X) | 1.09 | 1.14 | 1.14 | 1.10 | 1.12 |
| Quick Ratio (X) | 0.46 | 0.57 | 0.56 | 0.56 | 0.71 |
| Inventory Turnover Ratio (X) | 0.95 | 0.96 | 1.24 | 1.54 | 0.00 |
| Interest Coverage Ratio (X) | 1.95 | 2.28 | 0.74 | 1.56 | 1.14 |
| Interest Coverage Ratio (Post Tax) (X) | 1.04 | 1.34 | 0.15 | 1.03 | 0.47 |
| Enterprise Value (Cr.) | 106.16 | 129.47 | 109.32 | 94.69 | 104.74 |
| EV / Net Operating Revenue (X) | 1.72 | 1.89 | 1.40 | 1.28 | 1.83 |
| EV / EBITDA (X) | 9.39 | 9.96 | 22.84 | 7.84 | 12.91 |
| MarketCap / Net Operating Revenue (X) | 0.83 | 1.02 | 0.61 | 0.35 | 0.61 |
| Price / BV (X) | 0.89 | 1.22 | 0.85 | 0.45 | 0.60 |
| Price / Net Operating Revenue (X) | 0.83 | 1.02 | 0.61 | 0.35 | 0.61 |
| EarningsYield | 0.00 | 0.02 | -0.11 | 0.00 | -0.10 |
After reviewing the key financial ratios for Cian Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 0.10. This value is below the healthy minimum of 5. It has decreased from 0.81 (Mar 23) to 0.10, marking a decrease of 0.71.
- For Diluted EPS (Rs.), as of Mar 24, the value is 0.10. This value is below the healthy minimum of 5. It has decreased from 0.81 (Mar 23) to 0.10, marking a decrease of 0.71.
- For Cash EPS (Rs.), as of Mar 24, the value is 2.29. This value is below the healthy minimum of 3. It has decreased from 2.98 (Mar 23) to 2.29, marking a decrease of 0.69.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 23.10. It has increased from 23.00 (Mar 23) to 23.10, marking an increase of 0.10.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 23.10. It has increased from 23.00 (Mar 23) to 23.10, marking an increase of 0.10.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 24.68. It has decreased from 27.44 (Mar 23) to 24.68, marking a decrease of 2.76.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 4.52. This value is within the healthy range. It has decreased from 5.20 (Mar 23) to 4.52, marking a decrease of 0.68.
- For PBIT / Share (Rs.), as of Mar 24, the value is 2.34. This value is within the healthy range. It has decreased from 3.03 (Mar 23) to 2.34, marking a decrease of 0.69.
- For PBT / Share (Rs.), as of Mar 24, the value is 0.01. This value is within the healthy range. It has decreased from 0.79 (Mar 23) to 0.01, marking a decrease of 0.78.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 0.10. This value is below the healthy minimum of 2. It has decreased from 0.81 (Mar 23) to 0.10, marking a decrease of 0.71.
- For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 0.10. This value is below the healthy minimum of 2. It has decreased from 0.81 (Mar 23) to 0.10, marking a decrease of 0.71.
- For PBDIT Margin (%), as of Mar 24, the value is 18.32. This value is within the healthy range. It has decreased from 18.94 (Mar 23) to 18.32, marking a decrease of 0.62.
- For PBIT Margin (%), as of Mar 24, the value is 9.46. This value is below the healthy minimum of 10. It has decreased from 11.03 (Mar 23) to 9.46, marking a decrease of 1.57.
- For PBT Margin (%), as of Mar 24, the value is 0.07. This value is below the healthy minimum of 10. It has decreased from 2.90 (Mar 23) to 0.07, marking a decrease of 2.83.
- For Net Profit Margin (%), as of Mar 24, the value is 0.41. This value is below the healthy minimum of 5. It has decreased from 2.95 (Mar 23) to 0.41, marking a decrease of 2.54.
- For NP After MI And SOA Margin (%), as of Mar 24, the value is 0.41. This value is below the healthy minimum of 8. It has decreased from 2.95 (Mar 23) to 0.41, marking a decrease of 2.54.
- For Return on Networth / Equity (%), as of Mar 24, the value is 0.44. This value is below the healthy minimum of 15. It has decreased from 3.53 (Mar 23) to 0.44, marking a decrease of 3.09.
- For Return on Capital Employeed (%), as of Mar 24, the value is 6.14. This value is below the healthy minimum of 10. It has decreased from 7.94 (Mar 23) to 6.14, marking a decrease of 1.80.
- For Return On Assets (%), as of Mar 24, the value is 0.15. This value is below the healthy minimum of 5. It has decreased from 1.26 (Mar 23) to 0.15, marking a decrease of 1.11.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.47. This value is within the healthy range. It has decreased from 0.51 (Mar 23) to 0.47, marking a decrease of 0.04.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.96. This value is within the healthy range. It has decreased from 1.06 (Mar 23) to 0.96, marking a decrease of 0.10.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.38. It has decreased from 0.44 (Mar 23) to 0.38, marking a decrease of 0.06.
- For Current Ratio (X), as of Mar 24, the value is 1.09. This value is below the healthy minimum of 1.5. It has decreased from 1.14 (Mar 23) to 1.09, marking a decrease of 0.05.
- For Quick Ratio (X), as of Mar 24, the value is 0.46. This value is below the healthy minimum of 1. It has decreased from 0.57 (Mar 23) to 0.46, marking a decrease of 0.11.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.95. This value is below the healthy minimum of 4. It has decreased from 0.96 (Mar 23) to 0.95, marking a decrease of 0.01.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 1.95. This value is below the healthy minimum of 3. It has decreased from 2.28 (Mar 23) to 1.95, marking a decrease of 0.33.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 1.04. This value is below the healthy minimum of 3. It has decreased from 1.34 (Mar 23) to 1.04, marking a decrease of 0.30.
- For Enterprise Value (Cr.), as of Mar 24, the value is 106.16. It has decreased from 129.47 (Mar 23) to 106.16, marking a decrease of 23.31.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.72. This value is within the healthy range. It has decreased from 1.89 (Mar 23) to 1.72, marking a decrease of 0.17.
- For EV / EBITDA (X), as of Mar 24, the value is 9.39. This value is within the healthy range. It has decreased from 9.96 (Mar 23) to 9.39, marking a decrease of 0.57.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 1.02 (Mar 23) to 0.83, marking a decrease of 0.19.
- For Price / BV (X), as of Mar 24, the value is 0.89. This value is below the healthy minimum of 1. It has decreased from 1.22 (Mar 23) to 0.89, marking a decrease of 0.33.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 1.02 (Mar 23) to 0.83, marking a decrease of 0.19.
- For EarningsYield, as of Mar 24, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 23) to 0.00, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Cian Healthcare Ltd:
- Net Profit Margin: 0.41%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 6.14% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.44% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.04
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.46
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 53.76)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.96
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.41%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Milkat No. 3339, Block No.1, From South Side, Pune Maharashtra 412308 | cs@cian.co https://www.cian.co |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Suraj Shriniwas Zanwar | Managing Director |
| Mrs. Swati Maheshwari | Independent Director |
| Mr. Paresh Arun Shah | Non Executive Director |
| Mr. Sunil Saini | Independent Director |